Long-term Outcomes After Stepping Down Asthma Controller Medications
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- National Center for Advancing Translational Sciences
- Mayo Clinic (TL1 TR000137)
- Mayo Foundation for Medical Education and Research
This publication has 12 references indexed in Scilit:
- The risk of asthma exacerbation after reducing inhaled corticosteroids: a systematic review and meta‐analysis of randomized controlled trialsAllergy, 2014
- The risk of asthma exacerbation after stopping low-dose inhaled corticosteroids: A systematic review and meta-analysis of randomized controlled trialsJournal of Allergy and Clinical Immunology, 2013
- Long-Acting β2-Agonist Step-off in Patients With Controlled AsthmaArchives of internal medicine (1960), 2012
- Asthma outcomes: ExacerbationsJournal of Allergy and Clinical Immunology, 2012
- The impact of asthma medication guidelines on asthma controller use and on asthma exacerbation rates comparing 1997–1998 and 2004–2005Annals of Allergy, Asthma & Immunology, 2012
- Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trialThe Lancet, 2011
- The Controller-to-Total Asthma Medication Ratio Is Associated With Patient-Centered As Well As Utilization OutcomesChest, 2006
- Validation of a β-agonist long-term asthma control scale derived from computerized pharmacy dataJournal of Allergy and Clinical Immunology, 2006
- Effects of Reducing or Discontinuing Inhaled Budesonide in Patients with Mild AsthmaNew England Journal of Medicine, 1994
- Proportional hazards tests and diagnostics based on weighted residualsBiometrika, 1994